Wintrust Investments LLC grew its stake in Danaher Co. (NYSE:DHR – Free Report) by 8.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 7,793 shares of the conglomerate’s stock after buying an additional 590 shares during the quarter. Wintrust Investments LLC’s holdings in Danaher were worth $1,870,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of DHR. Charles Schwab Investment Management Inc. raised its holdings in Danaher by 1.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 3,655,397 shares of the conglomerate’s stock worth $877,295,000 after purchasing an additional 49,867 shares during the period. Tekla Capital Management LLC raised its holdings in Danaher by 35.1% in the 2nd quarter. Tekla Capital Management LLC now owns 142,813 shares of the conglomerate’s stock worth $34,275,000 after purchasing an additional 37,123 shares during the period. Blue Whale Capital LLP acquired a new position in Danaher in the 2nd quarter worth about $18,240,000. Humankind Investments LLC raised its holdings in Danaher by 12.4% in the 2nd quarter. Humankind Investments LLC now owns 4,201 shares of the conglomerate’s stock worth $290,000 after purchasing an additional 462 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Danaher by 11.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,468,146 shares of the conglomerate’s stock worth $832,335,000 after purchasing an additional 367,911 shares during the period. Institutional investors and hedge funds own 76.71% of the company’s stock.
Danaher Trading Up 2.3 %
Shares of Danaher stock opened at $208.16 on Thursday. The firm has a market capitalization of $153.82 billion, a price-to-earnings ratio of 26.25, a PEG ratio of 1.95 and a beta of 0.81. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.54. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.94 and a current ratio of 2.26. The stock has a 50 day moving average of $219.66 and a 200 day moving average of $235.27.
Danaher Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 27th. Investors of record on Thursday, October 12th were given a $0.27 dividend. The ex-dividend date was Wednesday, October 11th. This represents a $1.08 annualized dividend and a yield of 0.52%. Danaher’s payout ratio is 13.62%.
Insider Buying and Selling
In other Danaher news, SVP Jose-Carlos Gutierrez-Ramos sold 590 shares of the company’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $250.54, for a total transaction of $147,818.60. Following the transaction, the senior vice president now directly owns 6,939 shares in the company, valued at $1,738,497.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.10% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on the company. Stifel Nicolaus reduced their price target on Danaher from $250.00 to $240.00 and set a “hold” rating for the company in a report on Wednesday, July 26th. TheStreet lowered Danaher from a “b-” rating to a “c+” rating in a research note on Thursday, November 9th. The Goldman Sachs Group cut their price objective on Danaher from $250.00 to $215.00 and set a “buy” rating for the company in a research note on Thursday, October 26th. Royal Bank of Canada cut their price objective on Danaher from $246.00 to $239.00 and set an “outperform” rating for the company in a research note on Wednesday, October 25th. Finally, JPMorgan Chase & Co. cut their price objective on Danaher from $260.00 to $250.00 and set an “overweight” rating for the company in a research note on Wednesday, October 25th. Three research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $257.73.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions.
- Five stocks we like better than Danaher
- The Role Economic Reports Play in a Successful Investment Strategy
- Unlocking AI Investment Opportunities in Healthcare
- Canada Bond Market Holiday: How to Invest and Trade
- New Disney investor propels stock to ranks of best S&P gainers
- What Is Dividend Yield and How Do You Calculate It?
- Buffett’s latest portfolio additions, trims, and cuts in Q3
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.